On September 11, 2026, Nautilus Biotechnology entered into a new Sales Agreement with TD Securities (USA), LLC to sell shares of its common stock through an at-the-market offering program with aggregate sales proceeds of up to $125,000,000. The company simultaneously terminated the prior Sales Agreement dated February 28, 2024, under which no shares had been sold. TD Securities will act as sales agent and is entitled to compensation equal to up to 3.0% of gross proceeds. Nautilus Biotechnology operates in the biotechnology industry, developing diagnostic tests for cancer.

Nautilus Biotechnology reported financial results for the quarter ended June 30, 2026, recognizing its first revenue of $0.2 million from grant activities and its first Iterative Mapping Early Access Program customer. Operating expenses decreased 7% to $15.9 million, resulting in a net loss of $14.5 million compared to $15.0 million in the prior year period. The company holds $129.2 million in cash, cash equivalents, and investments. Management announced a strategic realignment to accelerate proteoform applications, with the Voyager Platform launch expected in early 2027 and consumable kits available by mid-2027. The Broadscale Portfolio timeline remains undetermined due to performance issues. Nautilus Biotechnology operates in the life sciences industry, developing a single-molecule proteome analysis platform.